The Queen’s University of Belfast Confidence in Concept programme 2016
Lead Research Organisation:
Queen's University Belfast
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
| James McElnay (Principal Investigator) |
Publications
McBride JW
(2019)
Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES.
in International journal of pharmaceutics
Quinn HL
(2016)
Dissolving microneedles: safety considerations and future perspectives.
in Therapeutic delivery
Johnston MC
(2020)
DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models.
in Journal of controlled release : official journal of the Controlled Release Society
Eltayib E
(2016)
Hydrogel-forming microneedle arrays: Potential for use in minimally-invasive lithium monitoring.
in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
Wang Y
(2018)
Intravaginal rings for continuous low-dose administration of cervical ripening agents
in International Journal of Pharmaceutics
Larrañeta E
(2016)
Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development
in Materials Science and Engineering: R: Reports
Kearney MC
(2016)
Microneedle-mediated delivery of donepezil: Potential for improved treatment options in Alzheimer's disease.
in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
Larrañeta E
(2016)
Microneedles: A New Frontier in Nanomedicine Delivery.
in Pharmaceutical research
Quinn HL
(2016)
Novel methods of drug administration for the treatment and care of older patients.
in International journal of pharmaceutics
| Description | Development of a novel tumour immunotherapy neoantigen vaccine |
| Amount | £148,684 (GBP) |
| Funding ID | INI PoC 703 |
| Organisation | Invest Northern Ireland |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 10/2019 |
| Description | Induced Pluripotent Stem Cell technology for Drug Discovery and Personalized Medicine |
| Amount | £206,360 (GBP) |
| Funding ID | 45418 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 11/2022 |
| Description | Nanoformulations for Sustained Intraocular Drug Delivery |
| Amount | £109,000 (GBP) |
| Organisation | Invest Northern Ireland |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | SEUPB INTERREG BREATH project |
| Amount | € 7,700,000 (EUR) |
| Organisation | European Union |
| Sector | Public |
| Country | European Union (EU) |
| Start | 11/2018 |
| End | 11/2023 |
| Description | Venture Capital Funding to Spin-out company Re-Vana Ltd |
| Amount | £1,243,229 (GBP) |
| Organisation | Syndicate Room Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Title | OCULAR COMPOSITIONS |
| Description | The invention provides methods of making microparticle and nanoparticle ocular implants from a composition comprising: 99 to 60 % (w/w) of a photopolymerizable composition selected from the group of fragments or monomers consisting of polyalkylene glycol diacrylate and polyalkylene glycol dimethacrylate, wherein the photopolymerizable composition has a molecular weight in the range of 100 to 20,000 Dalton; a biodegradable polymer selected from the group consisting of aliphatic polyester-based polyurethanes, polylactides, polycaprolactones, polyorthoesters and mixtures, copolymers, and block copolymers thereof; a photoinitiator; and a therapeutic agent. |
| IP Reference | WO2018206749 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | Commercial In Confidence |
| Impact | This IP portfolio has supported development of University's spin-out company - ReVana Therapeutics |
| Company Name | Re-Vana |
| Description | Re-Vana develops biodegradable drugs used in the treatment of eye diseases. |
| Year Established | 2016 |
| Impact | Impact development still in progress |
| Website | http://re-vana.com |
| Company Name | ReproGo |
| Description | ReproGo develops technology that produces stem-cells for specific patients. |
| Year Established | 2020 |
| Impact | The company attracted a total of £50K of support for customer discovery ant team formation from Innovate UK through ICURe, and was invited to apply for the aid for start-ups programme for ICURe companies. This was successfully awarded and company incorporated in 2020, although commencement of the award was delayed due to the coronavirus pandemic |
| Website | http://qubis.co.uk |
| Company Name | VascVersa |
| Description | VascVersa develops a stem cell retrieval method, allowing high potency cells to be obtained from small samples of umbilical cord blood, for use in regenerative medical research. |
| Year Established | 2018 |
| Impact | £42,500 was raised for the customer discovery and company set-up process from Innovate UK -ICURe programme. The company was invited to apply for £210K of non-dilutive Innovate UK funding (decision pending March 19) |
| Website | https://www.vascversa.com/ |